| BCBS Federal Medical & Drug | 2.04.51 Genotype-Guided Tamoxifen Treatment | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.101 Genetic Testing for Li-Fraumeni Syndrome | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.104 Genetic Testing for α-Thalassemia | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.110 Genetic Testing for Diagnosis and Management of Mental Health Conditions | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.119 Multibiomarker Disease Activity Blood Test for Rheumatoid Arthritis | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.123 Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.140 Proteogenomic Testing for Patients With Cancer | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.142 Molecular Testing in the Management of Pulmonary Nodules | 2025-09-01 |
| BCBS Federal Medical & Drug | 2.04.146 Gene Expression Profiling for Cutaneous Melanoma | 2025-09-01 |
| BCBS Federal Medical & Drug | 6.01.59 Coronary Computed Tomography Angiography With Selective Noninvasive Fractional Flow Reserve | 2025-09-01 |